secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2026-08-27T10:01:18+00:00
Accession:  0001193125-26-369426
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion shareholders approve merger proposals; 1-for-7 reverse split; redomestication fails
--------------------------------------------------------------------------------

- Shareholders approved Nasdaq issuance, authorized share increase to 700M, reverse split, and 2026 stock plans; redomestication to Cayman failed.
- Board set reverse split at 1-for-7, cutting shares from ~4.7M to ~0.7M; fractional shares paid in cash.
- Combined company to trade as Korsana Biosciences, Inc. (KRSA) on Nasdaq from Sept 9, 2026, with new CUSIP 23255M303.
- Redomestication failure not a condition to close; merger remains pending with closing conditions to be satisfied.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000119312526369426/0001193125-26-369426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000119312526369426/d264301d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-369426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer